Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Abilify Prolonged Release Aqueous Suspension for Intramuscular Injection Specified Drug-use Results Survey (Prevention of Recurrence/relapse of Mood Episodes in Bipolar I Disorder)

NCT04812379 is registered in ClinicalTrials.gov with Otsuka Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT04812379
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04812379 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Abilify Prolonged Release Aqueous Suspension for Intramuscular Injection Specified Drug-use Results Survey (Prevention of Recurrence/relapse of Mood Episodes in Bipolar I Disorder)
Lead sponsor
Otsuka Pharmaceutical Co., Ltd.
Phase
Observational
Overall status
Completed
Start date
April 7, 2021
Completion date
June 21, 2024
Enrollment
535 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar disorder i